Reducing the immunosuppressive microenvironment in pancreatic adenocarcinomas through cell-type specific targeting of myeloid derived suppressor cells

Pancreatic adenocarcinoma is one of the leading causes of cancer related deaths worldwide and currently lacks effective treatments. The immune-suppressive microenvironment and high malignancy has made conventional targeted therapies and immunotherapies ineffective for most patients. Thus, there is an urgent need for alternative treatments to enhance therapeutic efficacy. Through a comprehensive literature review, we propose a novel CD300ld antigen-specific liposome cargo delivery system for targeting MDSC mediated immune-suppression in pancreatic adenocarcinoma. Hypothetically, this approach could exhibit enhanced immune engagement and significant anti-tumor effects through the artificial expression of CD47 inhibitor and suppression of STAT3-dependent immunosuppressive cytokines. Further validation in primate models, combined with conventional immune check-point inhibitor (ICI) treatments, could be conducted for a more comprehensive understanding of this model.